Recombinant human IL-11

Recombinant human IL-11 was under evaluation in human clinical trials for use as a thrombopoietin product for chemotherapy support.18 An ELISA was developed to measure adsorption (residual concentration in various containers over time). The ELISA was formatted with an anti-IL-11 MAb for capture and a biotinylated antibody for detection.18 A combination of HSA and Tween-20 was required to address both the adsorption of IL-11 to glass and retention of biological activity postlyophilization. 

Recombinant human IL-11 (oprelvekin) is a polypeptide of 177 amino acids. It differs from natural IL-11 due to lack of glycosylation and the amino-terminal proline residue. Oprelvekin is administered by subcutaneous injection, usually 6-24 h after chemotherapy, at a dose of 25-50 p,g/kg per day. The drug has a half-life of about 7h. It is used to stimulate bone marrow to induce platelet production in nonmyeloid malignancies in patients undergoing chemotherapy. The common side effects of oprelvekin include fluid retention, tachycardia, edema, nausea, vomiting, diarrhea, shortness of breath and mouth sores. Other side effects include rash at the injection site, blurred vision, paresthesias, headache, fever, cough and bone pain. Rarely, CLS may occur. 

USP received a medication error report involving the products Neumega (oprel-vekin) and Proleukin (aldesleukin). Oprelvekin, a recombinant human interleukin-11 product used to stimulate platelet production in selected patients undergoing chemotherapy, is sometimes abbreviated as IL-11. Aldesleukin, a recombinant human interleukin-2 derivative indicated in designated patient populations for the treatment of metastatic renal-cell carcinoma, is sometimes abbreviated as IL-2. 

USA oprelvekin protein Neumega Recombinant human interleukin-11 including residues 2-178, human clone pXM/IL-11, lacking original N-terminal Pro, expressed in E. coli Thrombo- cytopenia... 

Oprelvekin, human recombinant IL-11, a thrombopoietic growth factor that stimulate stem cells and megakaryocyte progenitor, produced in E. coli... 

Chronic Proliferative Dermatitis The chronic proliferative dermatitis mutant mouse is one of a number of mouse models proposed for psoriasis. This spontaneous mutant was recently shown to be caused by a mutation in the Sharpin gene (86). This mouse model was used to screen recombinant human cytokines in which recombinant interleukin 12 (IL-12) but not interleukin 11 (IL-11) effectively corrected the skin disease (28). 

G2. Galy, A. H., Dinarello, C. A., Kupper, T. S., Kameda, A., and Hadden, J. W. Effects of cytokines on human thymic epithelial cells in culture. 11. Recombinant IL-1 stimulates thymic epithelial cells to produce IL-6 and GM-CSF. Cell Immunol. 129,161-175 (1990). 

---